P Valent

Summary

Affiliation: University of Vienna
Country: Austria

Publications

  1. ncbi Variable expression of activation-linked surface antigens on human mast cells in health and disease
    P Valent
    Department of Internal Medicine I, University of Vienna, Austria
    Immunol Rev 179:74-81. 2001
  2. ncbi Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Hematol J 3:90-4. 2002
  3. ncbi New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells
    P Valent
    Department of Internal Medicine I, The University of Vienna, Austria
    Thromb Haemost 87:786-90. 2002
  4. ncbi Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression
    Peter Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Austria
    Int Arch Allergy Immunol 127:137-9. 2002
  5. ncbi Signal transduction-associated and cell activation-linked antigens expressed in human mast cells
    Peter Valent
    Department of Internal Medicine I, University of Vienna, Austria
    Int J Hematol 75:357-62. 2002
  6. ncbi Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 114:3-11; quiz 12. 2004
  7. ncbi Assays for measuring in vitro basophil activation induced by recombinant allergens
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, The University of Vienna, Vienna, Austria
    Methods 32:265-70. 2004
  8. ncbi Diagnostic criteria and classification of mastocytosis: a consensus proposal
    P Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Währinger Gürtel 18 20 Vienna, Austria
    Leuk Res 25:603-25. 2001
  9. ncbi Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Leuk Res 25:595-602. 2001
  10. ncbi Mast cell proliferative disorders: current view on variants recognized by the World Health Organization
    Peter Valent
    Department of Internal Medicine 1, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Hematol Oncol Clin North Am 17:1227-41. 2003

Collaborators

Detail Information

Publications138 found, 100 shown here

  1. ncbi Variable expression of activation-linked surface antigens on human mast cells in health and disease
    P Valent
    Department of Internal Medicine I, University of Vienna, Austria
    Immunol Rev 179:74-81. 2001
    ..The present article gives an overview of MC phenotypes in health and disease, and attempts to provide explanations for the phenotypic variability of MC...
  2. ncbi Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Hematol J 3:90-4. 2002
    ..In the few patients recorded so far, a complex karyotype without recurring anomaly was found. The prognosis appears to be grave, although complete remission in response to chemotherapy has been described...
  3. ncbi New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells
    P Valent
    Department of Internal Medicine I, The University of Vienna, Austria
    Thromb Haemost 87:786-90. 2002
    ..Whether an altered availability of components of this cellular repair system can predispose for thrombophilia remains to be determined...
  4. ncbi Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression
    Peter Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Austria
    Int Arch Allergy Immunol 127:137-9. 2002
    ..In the present article, we discuss clinical and laboratory findings in smouldering SM and review the current literature. In addition, the pathophysiology of this novel subtype of SM is discussed...
  5. ncbi Signal transduction-associated and cell activation-linked antigens expressed in human mast cells
    Peter Valent
    Department of Internal Medicine I, University of Vienna, Austria
    Int J Hematol 75:357-62. 2002
    ..The current article gives an overview on signal transduction-associated and activation-linked antigens expressed in human MCs. Wherever possible the functional implication of signaling pathways and antigen expression are discussed...
  6. ncbi Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 114:3-11; quiz 12. 2004
    ..The current review provides an overview of mastocytosis and its subvariants and a practical guide that might help to delineate mastocytosis from unrelated systemic disorders...
  7. ncbi Assays for measuring in vitro basophil activation induced by recombinant allergens
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, The University of Vienna, Vienna, Austria
    Methods 32:265-70. 2004
    ..In the current article, the biochemical, functional, and technical background of these basophil tests is discussed...
  8. ncbi Diagnostic criteria and classification of mastocytosis: a consensus proposal
    P Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Währinger Gürtel 18 20 Vienna, Austria
    Leuk Res 25:603-25. 2001
    ..Criteria proposed in this article should be helpful in this regard...
  9. ncbi Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Leuk Res 25:595-602. 2001
    ..Whether these neoplasms display aberrant gene expression (or gene defects) or represent 'pre-pre-mast cell leukemias', remains unknown...
  10. ncbi Mast cell proliferative disorders: current view on variants recognized by the World Health Organization
    Peter Valent
    Department of Internal Medicine 1, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Hematol Oncol Clin North Am 17:1227-41. 2003
    ..In patients with SM-AHNMD, the SM should be treated as if no AHNMD is present, and the AHNMD should be treated as if no SM had been diagnosed...
  11. ncbi Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 115:515-36. 2003
    ..Recently established scoring systems aimed at predicting survival and evolution of leukemia in MDS may be helpful in this regard...
  12. ncbi Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Leuk Res 27:635-41. 2003
    ..This confirms clinical activity in some patients for this drug-combination, but also points to the need to search for more effective strategies in the treatment of patients with aggressive mast cell disorders...
  13. ncbi Diagnosis and treatment of systemic mastocytosis: state of the art
    Peter Valent
    Department of Internal Medicine I, Division of Haematology, University of Vienna, Austria
    Br J Haematol 122:695-717. 2003
  14. ncbi Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis
    P Valent
    Department of Internal Medicine, University of Vienna, Austria
    Blood 84:4322-32. 1994
    ....
  15. ncbi Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen
    S Vrtala
    Institute of General and Experimental Pathology, Vienna General Hospital, University of Vienna, Austria
    J Immunol 163:5489-96. 1999
    ....
  16. ncbi Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells
    W R Sperr
    Department of Internal Medicine I, University of Vienna, Austria
    Int Arch Allergy Immunol 102:170-5. 1993
    ..Furthermore, MCs could be desensitized specifically by pre-incubation of MCs with rhSCF in Ca-free medium. Together, these data suggest that SCF triggers mediator secretion from MCs in various organs via binding to the c-kit receptor...
  17. ncbi Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , 1090 Vienna, Austria
    Leuk Res 25:529-36. 2001
    ..These data suggest that cytomorphological assessment of bm MC in SM is an important diagnostic approach that may help to delineate between variants of the disease...
  18. ncbi Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells
    G H Schernthaner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Blood 98:3784-92. 2001
    ..These data show that neoplastic MCs express functionally active CD2. It is hypothesized that expression of CD2 is associated with pathologic accumulation and function of MCs in systemic mastocytosis...
  19. ncbi Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes
    W Füreder
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, The University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Eur J Clin Invest 31:894-901. 2001
    ..However, little is known so far about basophil granulocytes in MDS...
  20. ncbi Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell
    H Agis
    Department of Internal Medicine I, University of Vienna, Austria
    J Immunol 151:4221-7. 1993
    ..This is the first definitive demonstration that mast cells are replenished directly from early hemopoietic progenitors and thus form a unique cell lineage within the hemopoietic system...
  21. ncbi Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination
    T Ball
    Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Austria
    Allergy 64:569-80. 2009
    ..Our objective was the construction, purification and immunologic characterization of a genetically modified derivative of the major timothy grass pollen allergen, Phl p 1 for immunotherapy of grass pollen allergy...
  22. ncbi Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells
    M T Krauth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 39:1711-20. 2009
    ..However, these patients suffer not only from MC infiltration and consecutive organ damage but also from MC mediator-related symptoms...
  23. ncbi Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117/c-kit
    M Willheim
    Institute of General and Experimental Pathology, University of Vienna, Neubau AKH, Austria
    J Immunol Methods 182:115-29. 1995
    ..Thus, by combining isolation techniques including elutriation, magnetic cell depletion and cell sorting with mAb, functionally intact normal human basophils and mast cells can be enriched to homogeneity...
  24. ncbi Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells
    M T Krauth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 61:281-8. 2006
    ..The other statins tested (simvastatin, pravastatin) did not affect mediator release or growth of MCs. CONCLUSIONS: Cerivastatin and atorvastatin act as inhibitors of growth and function of human MCs...
  25. ncbi A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Leuk Res 25:627-34. 2001
    ..Because of the 'intermediate' clinical signs and absence of progression to aggressive disease, we proposed the term 'smouldering mastocytosis'...
  26. ncbi CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:797-806. 2008
    ..In conclusion, CD203c is a novel activation-linked surface antigen on MC that is upregulated in response to IgE receptor cross-linking and is overexpressed on neoplastic MC in patients with SM...
  27. ncbi Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L)
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Hum Pathol 32:545-52. 2001
    ..Apart from these, CD2 may be a novel useful marker because MCs in mastocytosis frequently express this antigen, whereas MCs in other pathologic conditions are CD2 negative...
  28. ncbi Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients
    K W Chen
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Allergy 67:609-21. 2012
    ..The aim of this study was to develop and characterize an allergy vaccine based on carrier-bound Der p 2 peptides, which should allow reducing IgE- and T-cell-mediated side-effects during specific immunotherapy (SIT)...
  29. ncbi Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Int J Immunopathol Pharmacol 20:267-78. 2007
    ..Compared to FcepsilonRI-mediated cell activation, IL-3-induced upregulation of CD203c is a late(r) event and is not accompanied by upregulation of CD63...
  30. ncbi Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry
    C Baumgartner
    Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 38:326-35. 2008
    ..In most cases, the bone marrow is involved. Expression of CD25 in bone marrow MC, with or without coexpression of CD2, is an important minor SM criterion. So far, most studies have examined CD25-expression on MC by flow cytometry...
  31. ncbi Clinical and biologic diversity of leukemias occurring in patients with mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Leuk Lymphoma 37:473-86. 2000
    ..In the present article, the concomitant occurrence of mastocytosis and leukemia is discussed in the light of the literature and of concepts proposed to explain the biologic basis of this phenomenon...
  32. ncbi Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Int Arch Allergy Immunol 122:279-86. 2000
    ..Whether such autoantibodies are recurrently produced in patients with Schnitzler's syndrome and play a role in the pathophysiology of the disease remains to be determined...
  33. ncbi Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients
    K Sonneck
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:11-21. 2008
    ..In aggregate, our data show that recombinant allergens promote expression of CD13 on basophils in sensitized individuals. The functional significance and diagnostic implications of this observation remain to be determined...
  34. ncbi Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression
    F Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:447-55. 2008
    ..Basophilic crisis and eosinophilia are well recognized features of advanced chronic myeloid leukaemia. In other myeloid neoplasms, however, transformation with marked basophilia and eosinophilia is considered unusual...
  35. ncbi Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin
    A Bugajska-Schretter
    Institute of Medical and Chemical Laboratory Diagnostics, AKH, University of Vienna, Austria
    Gut 46:661-9. 2000
    ..Almost 4% of the population suffer from food allergy which is an adverse reaction to food with an underlying immunological mechanism...
  36. ncbi Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms
    P Samorapoompichit
    Institute of Histology and Embryology, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Blood 98:2580-3. 2001
    ..Therefore, tryptase should not be regarded as specific for mast cells when neoplastic myeloid cells are analyzed...
  37. ncbi Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes
    F Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , A-1090, Vienna, Austria
    Leuk Res 25:287-94. 2001
    ..The LDH activity should be considered as an important prognostic factor in MDS...
  38. ncbi Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells
    A W Hauswirth
    Department of Medicine I, Medical University of Vienna, Austria
    Eur J Clin Invest 37:73-82. 2007
    ..In the present study, we asked whether leukaemic stem cells in patients with AML express CD33...
  39. ncbi IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease
    S Natter
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    Eur J Immunol 31:918-28. 2001
    ....
  40. ncbi Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, AKH, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    FASEB J 15:2042-4. 2001
    ..We thus demonstrate that synthetic hypoallergenic peptides derived from B cell epitopes of major allergens represent safe vaccine candidates for the treatment of IgE- mediated allergies...
  41. ncbi Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy
    T E Twaroch
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 42:966-75. 2012
    ..The mould Alternaria alternata is a major elicitor of allergic asthma. Diagnosis and specific immunotherapy (SIT) of Alternaria allergy are often limited by the insufficient quality of natural mould extracts...
  42. ncbi NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation
    E Hadzijusufovic
    Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria
    Allergy 67:858-68. 2012
    ..Kit mutations supposedly contribute to abnormal growth and drug resistance in these patients...
  43. ncbi Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:1525-33. 2004
    ..Almost 100 million allergic patients are sensitized to the major birch pollen allergen, Bet v 1, a 17 kDa protein containing most of the IgE epitopes present in pollens of trees belonging to the Fagales order and plant-derived food...
  44. ncbi Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7
    H Agis
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
    J Clin Pathol 59:396-402. 2006
    ..This approach should help in the quantification of bone marrow basophils at diagnosis and during anti-leukaemic treatment...
  45. ncbi Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)
    H Agis
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence for Clinical and Experimental Oncology CLEXO, Medical University of Vienna, Austria
    Ann Oncol 18:1834-41. 2007
    ..Therefore, monitoring of minimal residual disease (MRD) during treatment with imatinib is important. However, most MRD-parameters are expensive and require special technology. We determined the value of histamine as MRD-marker in CML...
  46. ncbi Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems
    W R Sperr
    Department of Internal Medicine I, University of Vienna, Austria
    Ann Hematol 80:272-7. 2001
    ..Karyotype-based multiparameter systems appear to be particularly effective in defining MDS patients who are at high risk of transforming to leukemia...
  47. ncbi Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors
    G-H Schernthaner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 60:1248-55. 2005
    ..Whereas IL-3R and GM-CSFRs are lost during differentiation of MC, these cells may acquire complement receptors (CD35, CD88) under the influence of distinct cytokines...
  48. ncbi Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
    C Sillaber
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:1098-109. 2009
    ..In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable...
  49. ncbi Vaccination with genetically engineered allergens prevents progression of allergic disease
    V Niederberger
    Department of Otorhinolaryngology, Vienna General Hospital, University of Vienna, 1090 Vienna, Austria
    Proc Natl Acad Sci U S A 101:14677-82. 2004
    ..Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease...
  50. ncbi Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells
    A Bohm
    Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:395-405. 2009
    ..Three mTOR-targeting drugs, rapamycin, everolimus (RAD001) and CCI-779, were applied. The effects of these drugs on growth, survival, apoptosis and VEGF expression in primary AML cells and various AML cell lines were examined...
  51. ncbi Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    K J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:869-73. 2008
    ..Cladribine (2CdA) and dasatinib are two drugs that counteract the in vitro growth of neoplastic mast cells in SM. However, only little is known about the in vivo effects of these drugs in SM...
  52. ncbi Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes
    F Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Ann Oncol 19:970-6. 2008
    ..In a screen program searching for dynamic prognostic determinants, we have identified lactate dehydrogenase (LDH) as a most suitable follow-up parameter...
  53. ncbi A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells
    S Laffer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 63:695-702. 2008
    ..In this study, we assessed the binding kinetics and affinity of monoclonal antibody 12 (mAb12) for IgE and investigated whether mAb12 can be used for depletion of IgE and isolation of IgE-bearing cells from peripheral blood...
  54. ncbi On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 34:41-52. 2004
    ..The therapeutic potential of target-specific approaches in malignant mast cell disorders should be evaluated in forthcoming clinical trials in the near future...
  55. ncbi Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Blood 98:2200-9. 2001
    ..Blast cell persistence or regrowth was associated with a persistently elevated level or recurrent increase of tryptase. Together, tryptase is expressed in myeloblasts in a group of AML and may serve as a useful disease-related marker...
  56. ncbi A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE
    S Laffer
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 108:409-16. 2001
    ..CONCLUSION: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells...
  57. ncbi Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand
    H C Bankl
    Department of Internal Medicine I, University of Vienna, Austria
    Circulation 91:275-83. 1995
    ..The role of redistributed MC and their mediators in the pathophysiology of atrial thrombosis requires further investigation...
  58. ncbi The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells
    H Herrmann
    Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    Curr Cancer Drug Targets 12:51-63. 2012
    ..Together, our data suggest that Hsp32 plays an important role as a survival factor in leukemic stem cells and as a potential new target in AML...
  59. ncbi Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
    A Weltermann
    Department of Internal Medicine I, Division of Haematology and Haemostasis, Vienna University Hospital, Vienna, Austria
    Leukemia 18:293-302. 2004
    ..In conclusion, our results indicate that both karyotype and the duration of first CR are independent prognostic factors for patients with de novo AML in first relapse...
  60. ncbi Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
    L L Remsing Rix
    Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Leukemia 23:477-85. 2009
    ..Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation...
  61. ncbi Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy
    P Samorapoompichit
    Centre of Anatomy and Cell Biology, Institute of Histology and Embryology, Medical University of Vienna, , A-1090 Vienna, Austria
    Histopathology 48:247-57. 2006
    ..CONCLUSION: Immunoelectron microscopy may be a helpful approach in confirming the identity of neoplastic MC in myeloid neoplasms...
  62. ncbi Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, A 1090 Vienna, Austria
    Ann Oncol 21:114-9. 2010
    ..The evaluation of comorbidity is of increasing importance in patients with hematologic disorders...
  63. ncbi Gastro-duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential
    T Eiwegger
    Department of Pediatrics, Division of General Pediatrics, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 36:1281-8. 2006
    ..CONCLUSION: Gastro-duodenal digestion fragments of Ara h 1 retain T cell stimulatory and IgE-binding and cross-linking properties of the intact protein...
  64. ncbi Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders
    J-H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , A-1090 Vienna, Austria
    Eur J Clin Invest 33:611-8. 2003
    ..An elevated CFU level in SM should raise the suspicion of an associated MPD (CMML) or smouldering SM, a novel SM-subtype that shares several features with MPD and sometimes progresses to an overt SM-MPD...
  65. ncbi Dasatinib inhibits progenitor cell proliferation from polycythaemia vera
    M Wappl
    Medical University of Vienna, Austria
    Eur J Clin Invest 38:578-84. 2008
    ..Since dasatinib is currently evaluated in patients with PV, it is of interest to study the effects of dasatinib on the growth of clonal progenitor cells in vitro...
  66. ncbi Expression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques
    F Wimazal
    Department of Internal Medicine I, University of Vienna, Austria
    Tissue Antigens 54:499-507. 1999
    ..In summary, Ba and MC express a unique profile of homing molecules. Apparently, Ba differ from MC in expression of recognition receptors relevant for binding to endothelium and consecutive transmigration...
  67. ncbi Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies
    M Ghannadan
    Department of Internal Medicine I, University of Vienna, Austria
    J Invest Dermatol 111:689-95. 1998
    ..In addition, foreskin MC, unlike MC from adult skin or lung, express CD88...
  68. ncbi Molecular characterization of dog albumin as a cross-reactive allergen
    S Spitzauer
    Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Austria
    J Allergy Clin Immunol 93:614-27. 1994
    ..Partial complementary DNA coding for dog albumin fragments may be considered a useful tool for further characterization of major IgE epitopes of dog albumin...
  69. ncbi Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies
    N Mothes
    Department of Pathophysiology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:1198-208. 2003
    ..These blocking antibodies may have protective effects by inhibiting immediate-type reactions and systemic increases of IgE responses caused by seasonal allergen exposure...
  70. ncbi Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829
    I Virgolini
    Department of Nuclear Medicine, University of Vienna, Austria
    Cancer Res 58:1850-9. 1998
    ..Because these receptors are frequently expressed at high levels on primary tumor cells, 99mTc-P829 appears to be a promising novel peptide tracer for tumor imaging...
  71. ncbi Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy
    S Li
    Department of Nuclear Medicine, University of Vienna, AKH, Ebene 3L, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Int J Cancer 91:789-96. 2001
    ..In comparison with (123)I-VEGF(121), (123)I-VEGF(165) bound to a higher number of different tumour cell types with a higher capacity. Thus, (123)I-VEGF(165) may be a potentially useful tracer for in vivo imaging of solid tumours...
  72. ncbi Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells
    S R Li
    Department of Nuclear Medicine, University of Vienna, Austria
    Life Sci 68:1243-57. 2001
    ..Our results suggest a direct effect of VIP and SST-14 on LDL-binding onto tumor cells. The complex interactions between VIP and SST-14 on LDL receptor expression of tumor cells may play a role in tumor cell lipid metabolism...
  73. ncbi Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology
    W R Sperr
    Medical University of Vienna, A 1090 Vienna, Austria
    Eur J Clin Invest 39:914-23. 2009
    ..Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in myeloid leukaemias. In several of these patients, increased serum tryptase levels are detectable...
  74. ncbi A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis
    H Agis
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, General Hospital Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Ann Hematol 81:90-5. 2002
    ..The increased frequency of numerical aberrations of chromosome 8 in patients with LC was the most interesting observation of our study. The pathophysiological significance of this finding remains to be determined...
  75. ncbi Characterization of recombinant cat albumin
    R Reininger
    Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:1695-702. 2003
    ..CONCLUSIONS: Recombinant cat albumin may be used as a paradigmatic tool to analyse mechanisms of allergen-triggered exacerbation of AD, for diagnostic and, perhaps for therapeutic purposes...
  76. ncbi Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies
    S Florian
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 61:1054-62. 2006
    ..Basophils (BA) and mast cells (MC) are important effector cells in allergic reactions. Development, growth and effector cell functions are regulated by a network of cytokines, other ligands, and respective cell surface antigens...
  77. ncbi Recognition sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense
    M Mayerhofer
    Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 20:421-34. 2007
    ..The current article provides an overview on MC antigens contributing to microbe recognition and targeting as an important element of natural host-defense...
  78. ncbi Characterization of Der p 21, a new important allergen derived from the gut of house dust mites
    M Weghofer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 63:758-67. 2008
    ..The house dust mite (HDM) Dermatophagoides pteronyssinus is a major allergen source eliciting allergic asthma. The aim of the study was to identify new important HDM allergens associated with allergic asthma...
  79. ncbi Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen
    M Binder
    Division of Specific Prophylaxis and Tropical Medicine and Immunopathology, Department of Pathophysiology, University of Vienna, Vienna, Austria
    J Immunol 167:5470-7. 2001
    ..Recombinant arginine kinase may be used to identify a group of polysensitized indoor allergic patients and for immunotherapy of these individuals...
  80. ncbi Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes
    A Berer
    Department of Internal Medicine I, Division of Hematology, University of Vienna, , 1090, Vienna, Austria
    Ann Hematol 82:271-7. 2003
    ..018) to predict survival in our patients. After inclusion of the IPSS risk categories, mCFU levels remained a highly predictive parameter for survival ( p=0.0056) and acute myeloblastic leukemia (AML) transformation ( p=0.0003)...
  81. ncbi Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
    T Nösslinger
    Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
    Ann Oncol 21:120-5. 2010
    ..The aim of this analysis was to study age and gender as interacting variables for individualized prognostication...
  82. ncbi Amplification of ribosomal RNA genes in acute myeloid leukemia
    C Fonatsch
    Institut für Medizinische Biologie der Universität Wien, Vienna, Austria
    Genes Chromosomes Cancer 32:11-7. 2001
    ..Modes of origin and clinical significance of the amplification of rRNA genes are discussed...
  83. ncbi Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients
    S Natter
    Institute of General and Experimental Pathology, AKH, University of Vienna, Austria
    FASEB J 12:1559-69. 1998
    ..Via binding to antigen presenting cells as well as to effector cells, IgE autoantigen immune complexes may contribute to exacerbation and/or perpetuation of severe atopic diseases even in the absence of exogenous allergens...
  84. ncbi Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
    R Fritsche-Polanz
    Department of Laboratory Medicine, Division of Endocrinology and Metabolism, University of Vienna, Vienna, Austria
    Br J Haematol 113:357-64. 2001
    ..The C-KIT 1642A-->C polymorphism is not associated with myelodysplastic syndrome or systemic mastocytosis...
  85. ncbi Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions
    P Valent
    Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:548-53. 2009
    ....
  86. ncbi Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells
    W Füreder
    Department of Internal Medicine, University of Vienna, Austria
    J Immunol 155:3152-60. 1995
    ....
  87. ncbi Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells
    Rudin Kondo
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Graduate School of Medical Sciences, Kumamoto University, Japan
    Blood 110:661-9. 2007
    ..Furthermore, both drugs were found to cooperate with PKC412 in producing growth inhibition. Together, these data show that Hsp32 is an important survival factor and interesting new therapeutic target in neoplastic MCs...
  88. ncbi Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens
    Matthias Mayerhofer
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    J Immunol 180:5466-76. 2008
    ..Based on all these results, it is hypothesized that KIT D816V as a single hit may be sufficient to cause indolent systemic mastocytosis, whereas additional defects may be required to induce aggressive mast cell disorders...
  89. ncbi Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils
    Maria Theresa Krauth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria
    Exp Hematol 35:108-16. 2007
    ..We have recently shown that mast cells (MCs) and basophils (BAs) express CD33. In the present study, we investigated the effects of GO on growth and mediator secretion in MCs and BAs...
  90. ncbi The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma
    Edgar Selzer
    Department of Radiotherapy and Radiobiology, University Hospital Vienna, 1090 Vienna, Austria
    Cancer Res 62:2098-103. 2002
    ..In conclusion, MITF-M may qualify as a marker capable of identifying subgroups of melanoma patients with different tumor biology and prognosis...
  91. ncbi Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412
    Karl J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Blood 109:3031-41. 2007
    ..1 cells and with PKC412 in HMC-1.2 cells. Together, these data show that MCL-1 is a novel survival factor and an attractive target in neoplastic MCs...
  92. ncbi A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    J Immunol 178:6290-6. 2007
    ..Using the hypoallergenic carp parvalbumin mutant Mut-CD/EF, it may be possible to treat fish allergy by immunotherapy...
  93. ncbi Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface
    Friedrich Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Res 31:1461-8. 2007
    ..The phrase "idiopathic cytopenia of undetermined significance (ICUS)", as also suggested by Mufti and co-workers, is proposed and long term follow-up is recommended to assess the evolution...
  94. ncbi Mastocytosis: state of the art
    Hans Peter Horny
    Institute of Pathology, Ansbach, Germany
    Pathobiology 74:121-32. 2007
    ....
  95. ncbi Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Exp Hematol 35:1510-21. 2007
    ..Clinical trials are now warranted to explore whether these TK inhibitors also counteract growth of neoplastic cells in vivo in patients with aggressive MC tumors...
  96. ncbi Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy
    Margit Weghofer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 147:101-9. 2008
    ..The aim of this study was to produce, by recombinant DNA technology, a folded Der p 5 allergen for diagnostic, therapeutic and preventive purposes...
  97. ncbi Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease
    Alexander W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria
    Hum Pathol 39:917-24. 2008
    ..The KIT mutation D816V was detected in sorted CD34(+) cells and unfractionated marrow cells but not in CD5(+) SLL cells, confirming the coexistence of 2 distinct neoplasms...
  98. ncbi Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Haematologica 92:1451-9. 2007
    ..The respective oncoprotein, KIT D816V, exhibits constitutive tyrosine kinase (TK) activity and has been implicated in malignant cell growth. Therefore, several attempts have been made to identify KIT D816V-targeting drugs...
  99. ncbi Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD8
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076 Tubingen, Germany
    J Mol Diagn 10:58-66. 2008
    ..Altogether, these data suggest that KIT(D816V+) SM can co-exist with JAK2(V617F+) CIMF and that, in some of these SM-CIMF cases, the two mutations are present in the neoplastic cells of both disease components...
  100. ncbi Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy
    Ines Swoboda
    Plant Molecular Biology and Biotechnology Laboratory, Institute of Land and Food Resources, The University of Melbourne, Parkville, Australia
    Eur J Immunol 32:270-80. 2002
    ..Our results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activity that represent potential vaccine candidates for immunotherapy of grass pollen allergy...
  101. ncbi Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment
    Cem Akin
    Department of Internal Medicine, University of Michigan, 4220 D MSRB 3, Box 0638, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0638, USA
    Curr Allergy Asthma Rep 6:282-8. 2006
    ..Flow cytometric analysis of bone marrow mast cells is therefore a sensitive method of diagnosis of mast cell disease and is expected to find increasing use in determining response to emerging mast cell cytoreductive therapies...